Wolverine Trading
AKBA icon

Wolverine Trading’s Akebia Therapeutics AKBA Stock Holding History

Wolverine Trading’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,200
Closed -$50.3K – 4670
2024
Q4 		$50.3K Sell
27,200
-20,900
-43% -$36.3K ﹤0.01% 4984
2024
Q3 		$64K Buy
+48,100
New +$64.2K ﹤0.01% 4483
2024
Q2 		– Sell
-34,600
Closed -$63.3K – 4404
2024
Q1 		$63.3K Sell
34,600
-5,800
-14% -$9.27K ﹤0.01% 4171
2023
Q4 		$50.1K Sell
40,400
-5,100
-11% -$5.2K ﹤0.01% 4258
2023
Q3 		$51.9K Buy
45,500
+13,500
+42% +$17.3K ﹤0.01% 4173
2023
Q2 		$29.6K Sell
32,000
-7,800
-20% -$7.53K ﹤0.01% 4054
2023
Q1 		$22K Buy
+39,800
New +$30.4K ﹤0.01% 3989
2022
Q4 		– Sell
-26,700
Closed -$8K – 3888
2022
Q3 		$8K Buy
+26,700
New +$10.5K ﹤0.01% 4460
2022
Q1 		– Sell
-19,400
Closed -$44K – 5329
2021
Q4 		$44K Buy
+19,400
New +$52.9K ﹤0.01% 5353
2021
Q3 		– Sell
-39,300
Closed -$152K – 6196
2021
Q2 		$152K Sell
39,300
-7,400
-16% -$24.9K ﹤0.01% 5189
2021
Q1 		$145K Buy
46,700
+13,600
+41% +$49K ﹤0.01% 5257
2020
Q4 		$99K Buy
33,100
+11,600
+54% +$33.9K ﹤0.01% 4463
2020
Q3 		$51K Buy
+21,500
New +$189K ﹤0.01% 4272
2020
Q2 		– Sell
-13,800
Closed -$110K – 4501
2020
Q1 		$110K Sell
13,800
-13,700
-50% -$107K ﹤0.01% 3979
2019
Q4 		$181K Sell
27,500
-2,300
-8% -$10.9K ﹤0.01% 4068
2019
Q3 		$123K Sell
29,800
-4,000
-12% -$17.1K ﹤0.01% 3784
2019
Q2 		$164K Buy
33,800
+2,800
+9% +$15.9K ﹤0.01% 3817
2019
Q1 		$254K Sell
31,000
-3,700
-11% -$25.4K ﹤0.01% 3551
2018
Q4 		$187K Buy
+34,700
New +$272K ﹤0.01% 3731

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wolverine Trading's AKBA Position: Q3 2023 in Review

Wolverine Trading sold out of Akebia Therapeutics (AKBA) in Q3 2023, closing a stake of 20,198 shares — an estimated $25.9K sold.

Wolverine Trading first reported a position in AKBA in Q2 2019 and held it in 10 quarters. The position peaked at $153K in Q2 2020. 76 funds tracked by Wall St. Rank hold AKBA as of Q3 2023.

  • Wolverine Trading reported no remaining Akebia Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Wolverine Trading sold 20,198 Akebia Therapeutics shares in Q3 2023, an estimated $25.9K.
  • Wolverine Trading first reported a position in Akebia Therapeutics in Q2 2019 and held it in 10 quarters.
  • Wolverine Trading's Akebia Therapeutics position peaked at $153K in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2023.

Based on Wolverine Trading's 13F filing for Q3 2023, filed 15 Nov 2023.